يعرض 1 - 20 نتائج من 72 نتيجة بحث عن '"Lutzky J"', وقت الاستعلام: 0.51s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
    Academic Journal
  3. 3
    Academic Journal
  4. 4
  5. 5
    Academic Journal

    Relation: Haydon, A., Alamgeer, M., Brungs, D., Collichio, F., Khushalani, N., Colevas, D., Rischin, D., Kudchadkar, R., Chai-Ho, W., Daniels, G., Lutzky, J., Lee, J., Bowyer, S., Migden, M., Silk, A., Lebbe, C., Grob, J. -J., Melero, I., Sheladia, P. ,. Hill, A. (2021). CERPASS: A RANDOMIZED, CONTROLLED, OPEN-LABEL, PHASE 2 STUDY OF CEMIPLIMAB +/- RP1 IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA. [Abstract]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 9 (Suppl 2), https://doi.org/10.1136/jitc-2021-SITC2021.547.; http://hdl.handle.net/11343/301708

  6. 6
    Academic Journal
  7. 7
  8. 8
    Academic Journal

    المساهمون: Antonia, S, Balmanoukian, A, Brahmer, J, Ou, S-H, Hellmann, M, Kim, S-W, Ahn, M-J, Kim, D-W, Gutierrez, M, Liu, S, Schöffski, P, Jäger, D, Jamal, R, Jerusalem, G, Lutzky, J, Nemunaitis, J, Calabro', L, Weiss, J, Gadgeel, S, Bhosle, J, Ascierto, P, Rebelatto, M, Narwal, R, Liang, M, Xiao, F, Antal, J, Abdullah, S, Angra, N, Gupta, Ak, Khleif, Sn, Segal, Nh

    مصطلحات موضوعية: Durvalumab, Efficacy, Immunotherapy, NSCLC, Safety

    وصف الملف: STAMPA

    Relation: info:eu-repo/semantics/altIdentifier/pmid/31228626; info:eu-repo/semantics/altIdentifier/wos/WOS:000487254200030; volume:14; issue:10; firstpage:1794; lastpage:1806; numberofpages:13; journal:JOURNAL OF THORACIC ONCOLOGY; https://hdl.handle.net/11392/2492559; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85071622278; https://www.jto.org/action/showPdf?pii=S1556-0864(19)30475-7; https://www.jto.org/article/S1556-0864(19)30475-7/fulltext

  9. 9
    Academic Journal

    المساهمون: Mateos M.-V., Blacklock H., Schjesvold F., Oriol A., Simpson D., George A., Goldschmidt H., Larocca A., Chanan-Khan A., Sherbenou D., Avivi I., Benyamini N., Iida S., Matsumoto M., Suzuki K., Ribrag V., Usmani S.Z., Jagannath S., Ocio E.M., Rodriguez-Otero P., San Miguel J., Kher U., Farooqui M., Liao J., Marinello P., Lonial S., Nicol A., Grigoriadis G., Catalano J., LeBlanc R., Elemary M., Bahlis N., Facon T., Karlin L., Attal M., Engelhardt M., Weisel K., Mackensen A., Nagler A., Ben Yehuda D., Magen-Nativ H., Palumbo A., Cavo M., Tobinai K., Chou T., Kosugi H., Taniwaki M., Sunami K., Ando K., Ganly P., Gjertsen B., Lahuerta J., Blade J., Oriol Rocafiguera A., Mateos M., Larson S., Atanackovic D., Devarakonda S., Bitran J., Zonder J., Morganstein N., Hay M., Saylors G., Kio E., Oliff I., Kirkel D., Shtivelband M., Yuen C., Yee A., Shah J., Htut M., Raza S., Chhabra S., Stiff P., Hari P., Bank B., Malek E., Gasparetto C., Faroun Y., Kreisle W., Singhal S., Rosenblatt J., Usmani S., Lee W., Safah H., Lutzky J., Suh J., Pan D., Baron A., Manges R., Steis R., Oliveira M., Moreb J., Callander N., Anz B., Raptis A., Stampleman L., Melear J., Boyd T., Garbo L.

    Relation: info:eu-repo/semantics/altIdentifier/pmid/31327687; info:eu-repo/semantics/altIdentifier/wos/WOS:000483400400009; volume:6; issue:9; firstpage:e459; lastpage:e469; numberofpages:11; journal:THE LANCET. HAEMATOLOGY; https://hdl.handle.net/2318/1742132; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85071223893; https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(19)30110-3/fulltext; https://doi.org/10.1016/s2352-3026(19)30110-3

  10. 10
  11. 11
  12. 12
    Conference

    المساهمون: Cleveland Clinic, Cleveland, OH

    Relation: https://dx.doi.org/10.1136/jitc-2022-SITC2022.0787; Gastman B, Sarnaik A, Lawrence D, Olszanski A, Chmielowski B, Lutzky J, et al. Delta-1: A Global, Multicenter, Phase 2 Study of Itil-168, an Unrestricted Autologous Tumorinfiltrating Lymphocyte (Til) Cell Therapy, in Adult Patients with Advanced Cutaneous Melanoma. Journal for immunotherapy of cancer. 2022 Nov;10:A819-A. PubMed PMID: WOS:000919423400743.; http://hdl.handle.net/10541/626280; Journal for Immunotherapy of Cancer

  13. 13
    Electronic Resource
  14. 14
    Electronic Resource
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
    Electronic Resource
  20. 20
    Electronic Resource